RT Journal Article
SR Electronic
T1 Progress, stasis, and regression through the hypertension care continuum: Longitudinal evidence from population-based cohort data in four populous middle-income countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.30.21256391
DO 10.1101/2021.04.30.21256391
A1 Mauer, Nicole
A1 Geldsetzer, Pascal
A1 Manne-Goehler, Jennifer
A1 Davies, Justine
A1 Stokes, Andrew C.
A1 McConnell, Margaret
A1 Ali, Mohammed K.
A1 Winkler, Volker
A1 Sudharsanan, Nikkil
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.04.30.21256391.abstract
AB Background Controlling and managing hypertension is a highly dynamic process yet, to our knowledge, existing evidence on hypertension control gaps in middle-income countries (MICs) is largely based on cross-sectional data. We provide the first longitudinal investigation of how individuals with hypertension move through the care continuum over time across multiple MICs.Methods We used multiple waves of population-based longitudinal cohort data from China, Indonesia, Mexico and South Africa. Based on measured blood pressure and information on hypertension diagnosis and treatment status, we classified adults aged 40 + into four care stages at both the baseline and follow-up waves: undiagnosed; diagnosed and untreated; diagnosed, treated, but uncontrolled (systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg); diagnosed, treated, and controlled (SBP < 140 mmHg and DBP < 90 mmHg). We estimated the probability of individuals progressing forward or regressing backwards through the continuum over a five-to nine-year between-wave period and investigated how these probabilities varied by age, sex, household location and educational attainment using Poisson regression models. We also estimated the probabilities of important clinical transitions (e.g. becoming diagnosed or treated; achieving blood pressure control; discontinuing treatment and losing blood pressure control).Findings Our data included 8359 individuals with hypertension (China: N=1371, Indonesia: N= 3438, Mexico: N=1946, South Africa: N=1604). Across all countries, there was a less than 50% probability of forward progression through the care continuum over time. Just over one in four undiagnosed individuals became diagnosed (China 30% [95% CI 26-33%], Indonesia 30% [95% CI 28-32%], Mexico 27% [95% CI 25-29%], South Africa 37% [95% CI 34-39%]) and one in three diagnosed, untreated individuals became treated (Indonesia 17% [95% CI 14-21%], Mexico 30% [95% CI 28-32%], China 48% [95% CI 39-56%], South Africa 42% [95% CI 40-44%]). Importantly, there were very high probabilities of regressing to less advanced continuum stages: up to nine in ten treated and controlled individuals lost blood pressure control (Indonesia 92% [95% CI 88-95%], Mexico 77% [95% CI 72-81%], China 76% [95% CI 68-83%], South Africa 48% [95% CI 42-54%]) and up to three in four individuals discontinued treatment over the follow-up period (China 36% [95% CI 32-41%], Indonesia 70% [95% CI 67-73%], Mexico 34% [5% CI 32-36%], South Africa 25% [23-27%]). Individuals from rural households were disadvantaged in all countries but China, while females were more likely to progress through the continuum in Indonesia and Mexico.Interpretation Our results uncover critical gaps in hypertension care in MICs in both early and late stages of the continuum. Adopting a longitudinal perspective reveals that policies solely aimed at improving diagnosis or initiating treatment may not lead to large improvements in control, as treatment initiation rates are low and achievement of blood pressure control and adherence to therapy are rarely sustained over time.Evidence before this study We searched PubMed for articles published from database inception until January 1st, 2021 using variations of the search terms “blood pressure”, “hypertension”, “continuum”, “cascade”, “treatment”, “diagnosis”, “control”, “treated”, “diagnosed”, “controlled” to screen titles and abstracts. The currently largest studies estimating nationally representative levels of hypertension diagnosis, treatment and control across multiple low- and middle-income countries (LMICs) are the Prospective Urban Rural Epidemiology (PURE) study from 2013, which included 140 000 individuals across 14 LMICs and a more recent study based on 1·1 million adults in 44 LMICs from 2019. Both studies highlight important gaps in awareness, diagnosis, treatment and control of hypertension across populations in LMICs. However, these and smaller non-nationally representative or single country studies are all based on cross-sectional data and none capture the dynamic nature of chronic disease care and how individuals move through the hypertension care continuum over time.Added value of this study To our knowledge, we provide the first longitudinal evidence on how individuals with hypertension in middle-income countries (MICs) move through the hypertension care continuum over time using country-wide, longitudinal cohort data from four MICs, which span three different continents and account for close to one-fourth of the world population. The longitudinal perspective provides new insights over existing cross-sectional cascades by capturing critical dynamic elements of chronic disease management, such as how individuals arrived at a specific continuum stage or whether they move forward or backward through continuum stages over time.Implications of all available evidence Our results reveal that individuals rarely sustain blood pressure control and that they tend to discontinue treatment over time. These results can inform efforts to improve hypertension control by revealing the need to move beyond policies aimed solely at screening and diagnosis to those that also aim to help individuals sustain blood pressure control over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was exempt from institutional review board approval because the data are publicly available and deidentified. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data employed are publicly available and freely downloadable at the respective websites of the China Health and Nutrition Survey (CHNS), the Indonesian Family Life Survey (IFLS), the Mexican Family Life Survey (MxFLS) and the South African National Income Dynamics Study (NIDS). All code used for data analysis will be made available on the corresponding author's website.